GlassScriptPhysician profile
Jennifer M Rahn
NPI 1356381602
$13,077.91
in general payments reported to CMS, 2019-2025
28 companies · $2,324 in 2025
The $2,324 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,739 · 2022: $2,427 · 2023: $2,888 · 2024: $2,700 · 2025: $2,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,668 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,667.87 |
| Education | $243.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,231.62 | 2021-2025 | Enbrel, Evenity, Tavneos |
| Abbvie INC. | $1,705.79 | 2021-2025 | |
| Ucb, INC. | $1,516.44 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,469.89 | 2021-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $1,070.92 | 2021-2025 | Acthar |
| Pfizer INC. | $818.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $723.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $669.79 | 2021-2025 | Saphnelo, Evusheld |
| Lilly USA, LLC | $621.70 | 2021-2025 | Taltz |
| Radius Health, INC. | $395.66 | 2021-2025 | Tymlos |
| Genzyme Corporation | $256.84 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $235.95 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $211.45 | 2021-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $192.85 | 2022-2025 | Purified Cortrophin Gel |
| Organon LLC | $171.59 | 2023-2025 | Renflexis, Hadlima |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.57 | 2023-2024 | Cyltezo, Spevigo |
| Johnson & Johnson Health Care Systems INC. | $103.57 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $98.14 | 2023-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $87.27 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $79.13 | 2021-2025 | Actemra |
| Horizon Therapeutics Plc | $56.29 | 2021 | |
| Sandoz INC. | $51.21 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $40.60 | 2023-2025 | Idacio |
| Ultragenyx Pharmaceutical INC. | $34.85 | 2021 | |
| Pacira Therapeutics, INC. | $30.92 | 2021 | |
| Eisai INC. | $28.69 | 2025 | |
| Alvogen INC | $24.54 | 2024 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $20.82 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Rahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.